A Case of Organizing Pneumonia (OP) Associated with Pembrolizumab
Drug Target Insights · 22.05.2016 · 10 (1)
DOI: 10.33393/dti.2016.1420 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Target Insights, online erschienen am 22.05.2016. Verfasst von Paraskevi Fragkou und 5 weiteren Autor:innen. Die Arbeit wurde bisher 10-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Until recently, chemotherapy for metastatic melanoma had disappointing results. The identification of immune checkpoints such as CTLA-4 and PD-1/PD-L1 has led to the development of an array of monoclonal antibodies (Mabs). These immunologic approaches against tumoral cells come with a novel kind of side effects that the clinician needs to be familiarized with. Herein, we report for the first time a case of organizing pneumonia, based on imaging and cytological analyses of bronchoalveolar lavage, possibly associated with the use of pembrolizumab, an anti-PD-1 Mab recently approved for the treatment of metastatic melanoma.
Zitieren
APA
Fragkou, P., Souli, M., Theochari, M., Kontopoulou, C., Loukides, S., & Koumarianou, A. (2016). A Case of Organizing Pneumonia (OP) Associated with Pembrolizumab. Drug Target Insights, 10(1). https://doi.org/10.33393/dti.2016.1420
Vancouver
Fragkou P, Souli M, Theochari M, Kontopoulou C, Loukides S, Koumarianou A. A Case of Organizing Pneumonia (OP) Associated with Pembrolizumab. Drug Target Insights. 2016;10(1). doi:10.33393/dti.2016.1420
BibTeX
@article{Fragkou2016,
author = {Fragkou, Paraskevi and Souli, Maria and Theochari, Maria and Kontopoulou, Christina and Loukides, Stelios and Koumarianou, Anna},
title = {A Case of Organizing Pneumonia (OP) Associated with Pembrolizumab},
journal = {Drug Target Insights},
year = {2016},
volume = {10},
number = {1},
doi = {10.33393/dti.2016.1420}
}
EUVIMED